x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:13:45

When Topicals Fail: The New IPC Consensus Every...

ReachMD CME ·

2025/12/22

CME credits: 0.25Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/ This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic

en

00:05:00

Hepatic Encephalopathy: More Common Than You Think

ReachMD CME ·

2025/12/11

CME credits: 1.00Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and

en

00:14:30

A Clear Horizon in Plaque Psoriasis: An Update on...

ReachMD CME ·

2025/11/26

CME credits: 0.25Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and

en

00:10:30

Engaging Your Patient: Shared Decision-Making in HF...

ReachMD CME ·

2025/11/18

CME credits: 0.25 Valid until: 18-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/ Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and

en

00:06:15

MOA: CDH6-Targeted Antibody-Drug Conjugates

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver

en

00:06:45

Clinical Evidence: Insights From Early Trials of...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:29:30

The Fifth Pillar? Closing the Gap in HFrEF

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-fifth-pillar-closing-the-gap-in-hfref/37615/ For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of quadruple pharmacologic guideline-directed medical therapy (GDMT) and medical

en

00:07:00

Looking Ahead: Integrating CDH6-Targeted Therapies...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the

en

00:07:15

Safety and Tolerability of CDH6-Directed...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:05:30

Navigating the Therapeutic Landscape of...

ReachMD CME ·

2025/11/14

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific

en

00:16:30

Advancing gMG Clinical Decisions: Diagnosing Early,...

ReachMD CME ·

2025/11/13

CME credits: 0.25 Valid until: 15-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-gmg-clinical-decisions-diagnosing-early-treating-smarter-and-caring-holistically-a-case-based-treatment-approach/36276/ This case-based discussion follows Maria, a 38-year-old teacher presenting with fluctuating ptosis, diplopia, and fatigue—classic but easily overlooked signs of generalized myasthenia gravis (gMG). Drs. Goyal and Edmundson review diagnostic strategies for gMG,

en

00:16:15

Treating MASH With Compensated Cirrhosis: A Serious...

ReachMD CME ·

2025/11/11

CME credits: 0.25 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-mash-with-compensated-cirrhosis-a-serious-unmet-need/37646/ Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify

en

00:42:00

Advancing Clinical Expertise in CELMoDs: Transforming...

ReachMD CME ·

2025/11/10

CME credits: 1.00 Valid until: 10-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-clinical-expertise-in-celmods-transforming-multiple-myeloma-treatment/35631/ This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge

en

00:00:00

Updates in Major Depressive Disorder with Insomnia

ReachMD CME ·

2025/11/07

CME credits: 0.50Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in

en

00:22:30

The Hidden Threat: Transforming CKD Care Across the...

ReachMD CME ·

2025/11/05

CME credits: 0.50 Valid until: 05-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-hidden-threat-transforming-ckd-care-across-the-diabetes-spectrum/36523/ Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and guideline

en

00:05:45

Screening for Cervical Cancer

ReachMD CME ·

2025/10/31

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Screening-for-Cervical-Cancer/39290/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens, highlighting the clinical

en

00:05:15

Evidence Base for Treatment Strategies for...

ReachMD CME ·

2025/10/31

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-Treatment-Strategies-for-Endometrial-Cancer-After-Disease-Progression-and-Interdisciplinary-Collaboration/39295/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the

en

00:05:30

Interdisciplinary Management of Gynecologic Cancers

ReachMD CME ·

2025/10/31

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Interdisciplinary-Management-of-Gynecologic-Cancers/39286/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into guideline-driven treatment regimens,

en

00:04:15

Evidence- and Guideline-Based Treatment for...

ReachMD CME ·

2025/10/31

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-and-Guideline-Based-Treatment-for-Advanced-Metastatic-Cervical-Cancer/39292/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the integration of immunotherapy into

en

00:17:30

Case-Based Approach: Optimizing...

ReachMD CME ·

2025/10/31

CME credits: 0.25 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-based-approach-optimizing-cardio-kidney-metabolic-outcomes-in-individuals-with-t2d-ckd/29906/ This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence

en

359 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事